Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Almirall SA (PK) ALMRY

Alternate Symbol(s):  LBTSF

Healthcare Drug Manufacturers - Specialty & Generic
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism... see more

Current News (PINL:ALMRY)

Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1

PR Newswire July 25, 2022

Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance

PR Newswire May 9, 2022

Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall

PR Newswire February 21, 2022

Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers

PR Newswire February 21, 2022

Almirall delivers solid nine months 2021 results and tightens its upgraded guidance

PR Newswire November 15, 2021

Almirall U.S. Supports The Skin Cancer Foundation's Mobile Skin Cancer Screening Program

PR Newswire November 8, 2021

Almirall delivers robust H1 performance and increases full-year guidance

PR Newswire July 26, 2021

Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis

PR Newswire July 19, 2021

Almirall receives positive CHMP opinion for Klisyri®? (tirbanibulin), an innovative topical treatment for actinic keratosis

PR Newswire May 21, 2021
View More News ››

Opinion & Analysis (PINL:ALMRY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:ALMRY)

Be the first to post on this bullboard.

SEGO Resources Inc.

SEGO Resources Inc.

Sego Resources Inc., an exploration stage company, engages in the acquisition, exploration, and evaluation of mineral ...
View More »

Podcasts